Humana Inc.’s stock price dips to $350.36, recording a 1.92% decrease: Is it time to buy?

Humana Inc. (HUM)

350.36 USD -6.87 (-1.92%) Volume: 0.75M

Humana Inc.’s stock price is currently valued at 350.36 USD, experiencing a slight dip of -1.92% this trading session with a trading volume of 0.75M. Despite these fluctuations, the healthcare giant’s stock has seen a significant percentage change YTD of -23.47%, indicating a volatile market performance.

Latest developments on Humana Inc.

Humana Inc. has been making headlines recently with a $90 million Medicare drug fraud settlement and the announcement of a new veteran hiring strategy, solidifying its reputation as a top veteran-friendly company. Despite these positive developments, the company’s stock underperformed compared to its competitors on Wednesday. Analysts are speculating about the next major corporation to emerge in downtown Louisville, wondering if it will follow in Humana’s footsteps. Additionally, Humana Inc. recently declared a quarterly dividend of $0.89 per share and is expected to post earnings of $3.45 per share in Q3 2024. Investors are closely watching Seth Klarman’s strategic moves as he takes a closer look at Humana Inc‘s prominent position in the market. With acquisitions by Dynamic Advisor Solutions LLC and increased stock holdings by Sequoia Financial Advisors LLC, Humana Inc. continues to attract attention from investors.

Humana Inc. on Smartkarma

Analysts at Baptista Research have provided bullish insights on Humana Inc. They highlighted the company’s enhanced strategic management of benefit costs and member acquisition tactics as major drivers for its performance. Humana’s first-quarter results for 2024 showed a mixed set of results but with adjusted expectations for the upcoming year. The company reaffirmed its full-year adjusted EPS guidance at approximately $16 and increased its membership growth outlook, showcasing operational resilience and strategic expansions.

In another report by Baptista Research, analysts discussed the impacts on Pharmacy Benefit Managers (PBMs) resulting from IRA changes and other major drivers affecting Humana Inc. CEO Bruce Broussard and CFO Susan Diamond shared insights during a Q&A session following the earnings call. Broussard highlighted Humana’s solid start to 2024 and reaffirmed the full-year adjusted earnings per share (EPS) guidance at around $16, along with an increased individual MA membership growth outlook. This information provides investors with valuable insights into the company’s financial performance and future outlook.

A look at Humana Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Humana Inc. has a positive long-term outlook. With a high Value score of 4, the company is considered to be undervalued in the market. This indicates that investors may see potential for growth in the company’s stock price in the future. Additionally, Humana Inc. has strong Momentum with a score of 4, suggesting that the company is performing well in the market compared to its peers.

While Humana Inc. has solid scores in Value and Momentum, its scores for Dividend, Growth, and Resilience are all moderate at 3. This indicates that the company may not be the top performer in these areas, but still maintains a stable position. Overall, Humana Inc. is a managed health care company that offers coordinated health care services to a variety of customers, including employer groups, government-sponsored plans, and individuals in the United States and Puerto Rico.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma